ClinicalTrials.gg
Not yet recruitingNCT06785831NutriPlantUpdated Jan 21, 2025

NutriPlant - Opportunities for Increasing Consumption of Local Fruits and Vegetables

An interventional study of Psyllium and Sauerkraut in Functional Constipation and Irritable Bowel Syndrome, sponsored by Nutrition Institute, Slovenia. Not yet recruiting at 1 site in Slovenia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-21.

Sponsored by Nutrition Institute, Slovenia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The effects of different foods to normal bowel function in adult population will be investigated. A randomised controlled intervention trial will be conducted on about 120 (30 per group) adult (18-70 years) subjects with functional constipation and irritable bowel syndrome with constipation according to the IV. Rome criteria. At least one week before inclusion in the study, patients will stop taking laxatives and other anti-constipation medications. Subjects will be randomly selected to consume one of the test foods (fresh apples, dried apples, sauerkraut) or the active control (psyllium) in the equivalent amount of 3 g of fiber per day for 4 weeks. Subjects will be asked not to change their lifestyle habits, such as diet and physical activity level, and not to take oral laxatives during the period of participation in the study.

02

Conditions studied

  • Functional Constipation
  • Irritable Bowel Syndrome
03

In context

Irritable Bowel Syndrome

1,116 studies on the registry are indexed under Irritable Bowel Syndrome; 208 are open to participants now.

This study's planned enrollment of 120 is above the median of 70 across 896 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

Nutrition Institute, Slovenia is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed of the participant to participate in the study

    • Age between 18 and 70 years
    • Functional constipation or irritable bowel syndrome
    • Expressed willingness to eat the investigated food daily (sauerkraut, apples, dried apples or psyllium; period of four weeks)

Exclusion criteria

  • Known allergy to the investigated foods (fresh apples, dried apples, sauerkraut or psyllium)

    • Pregnancy or breastfeeding
    • Previous gastrointestinal surgery with the exception of cholecystectomy and appendectomy
    • Other gastrointestinal diseases (chronic inflammatory bowel disease, celiac disease, gastroparesis, etc.)
    • Serious chronic diseases
    • Introduction of extensive changes in diet or physical activity in the last 4 weeks before the inclusion examination
    • Regular use of laxatives or inability to stop using laxatives for the duration of the study
    • Concurrent participation in another study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Psyllium

    Psyllium containing 3 g dietary fibre, daily, for 4 weeks

    Other: Psyllium

  • Experimental
    Sauerkraut

    Sauerkraut containing 3 g dietary fibre, daily, for 4 weeks

    Other: Sauerkraut

  • Experimental
    Fresh apples

    Fresh apples containing 3 g dietary fibre, daily, for 4 weeks

    Other: Fresh apples

  • Experimental
    Dried apples

    Dried apples containing 3 g dietary fibre, daily, for 4 weeks

    Other: Dried apples

Interventions

  • OtherPsyllium

    Participants will once daily consume predefined amount of psyllium, corresponding to 3 g of dietary fibre, for 28 days.

  • OtherSauerkraut

    Participants will once daily consume predefined amount of sauerkraut, corresponding to 3 g of dietary fibre, for 28 days.

  • OtherFresh apples

    Participants will once daily consume predefined amount of fresh apples, corresponding to 3 g of dietary fibre, for 28 days.

  • OtherDried apples

    Participants will once daily consume predefined amount of dried apples, corresponding to 3 g of dietary fibre, for 28 days.

06

What researchers measure

Primary outcomes

  1. Change in frequency of complete spontaneous bowel movements (CSBM) / week

    Daily measurement of number of complete spontaneous bowel movements

    Time frame: fourth week vs pre-intervention

Other outcomes

  1. Change in constipation symptom score (CSC)

    Measurement with constipation symptom score (0-48 points, higher SCS score mean more severe symptoms)

    Time frame: fourth week vs pre-intervention

  2. Change in stool consistency using Bristol stool form (BSF) scale

    Measurement with Bristol stool form (BSF) scale (Type 1: Separate hard lumps, like nuts (difficult to pass), Type 2: Sausage-shaped, but lumpy, Type 3: Like a sausage but with cracks on its surface, Type 4: Like a sausage or snake, smooth and soft (average stool), Type 5: Soft blobs with clear cut edges, Type 6: Fluffy pieces with ragged edges, a mushy stool (diarrhea), Type 7: Watery, no solid pieces, entirely liquid (diarrhea))

    Time frame: fourth week vs pre-intervention

  3. Change in blood lipids

    Laboratory measuremnt of S-Cholesterol, S-HDL-Cholesterol, S-LDL-Cholesterol and S-Triglycerides

    Time frame: in week after intervention vs pre-intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Sep 2025, 7 months later.

Of 305 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 7 months is below that.

Counting every sponsor, half of 357 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Jan 21, 2025
StartEst.
Jan 20, 2025
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 30, 2026
Last update
Jan 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06785831
Lead sponsor
Nutrition Institute, Slovenia
Collaborators
University Medical Centre Ljubljana, University of Ljubljana
Responsible party
Sponsor
First posted
Jan 21, 2025
Start date
Jan 20, 2025 (estimated)
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 21, 2025

Study contacts

Anita Kušar, PhD
Contact
anita.kusar@nutris.org
0038659068870
Igor Pravst, PhD
Contact
igor.pravst@nutris.org
0038659068871
Anita Kušar, PhD
study director · Researcher

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion